First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Trial Identifier: TED16132
Sponsor: Sanofi
Start Date: August 2019
Primary Completion Date: August 2022
Study Completion Date: September 2023
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CZECHIA Brno, CZECHIA, 62500
CZECHIA Ostrava - Poruba, CZECHIA, 70852
CZECHIA Praha 2, CZECHIA, 12808
FRANCE TOULOUSE Cedex 9, FRANCE, 31059
GREECE Athens, GREECE, 11528
SPAIN, Salamanca Salamanca, SPAIN, 37007
TAIWAN, PROVINCE OF CHINA TAIPEI, TAIWAN, PROVINCE OF CHINA, 10002
UNITED STATES, California Duarte, California, UNITED STATES, 91010
UNITED STATES, Massachusetts Boston, Massachusetts, UNITED STATES, 02115
UNITED STATES, Minnesota Rochester, Minnesota, UNITED STATES, 55905
UNITED STATES, North Carolina Chapel Hill, North Carolina, UNITED STATES, 27599
UNITED STATES, Wisconsin Milwaukee, Wisconsin, UNITED STATES, 53226